10x Genomics, Inc. TXG Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $473.97M+37.8% | $344.07M-4.2% | $359.28M+58.0% | $227.35M-61.9% | ||
| $49.44M+0.2% | $49.34M+67.7% | $29.41M-86.0% | $210.24M— | ||
| $193.32M-45.4% | $353.87M-7.9% | $384.3M+12.9% | $340.49M+21.3% | ||
| $261.98M-24.9% | $348.62M+8.7% | $320.62M+8.8% | $294.6M+52.1% | ||
| $684.45M+17.1% | $584.39M-2.0% | $596.02M-6.1% | $635.04M-15.1% | ||
| $226.71M-10.3% | $252.65M-9.6% | $279.57M-3.4% | $289.33M+70.7% | ||
| $4.51M0.0% | $4.51M0.0% | $4.51M0.0% | $4.51M0.0% | ||
| $62.33M+298% | $15.67M-5.7% | $16.62M-27.3% | $22.86M-10.0% | ||
| $1.04B+13.4% | $918.64M-4.8% | $965.14M-6.2% | $1.03B+1.0% | ||
| $56.81M-29.5% | $80.58M-7.4% | $87.02M-2.1% | $88.88M+34.4% | ||
| $23.9M+15.7% | $20.66M+57.1% | $13.15M+67.2% | $7.87M+47.3% | ||
| $153.45M+30.5% | $117.63M-7.5% | $127.16M-2.9% | $130.96M+18.7% | ||
| $245.04M+17.5% | $208.5M-7.0% | $224.1M+0.4% | $223.24M+10.9% | ||
| $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | ||
| -$1.51B-3.0% | -$1.47B-14.2% | -$1.28B-24.8% | -$1.03B-19.2% | ||
| $796.33M+12.1% | $710.13M-4.2% | $741.04M-8.0% | $805.74M-1.4% | ||
| $1.04B+13.4% | $918.64M-4.8% | $965.14M-6.2% | $1.03B+1.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can 10x Genomics, Inc. cover its short-term obligations?
- Its current ratio is 5.90 — current assets exceed current liabilities.
- Where does 10x Genomics, Inc.'s balance sheet data come from?
- Every line is extracted from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.